Real-world evaluation of the effectiveness and safety of dupilumab in bullous pemphigoid: an ambispective multicentre case series
Nidia Planella‐Fontanillas, Xavier Bosch‐Amate, Alicia Jiménez Antón, Carlos Moreno‐Vílchez, María Gamo Guerrero, María del Mar Blanes Martínez, María Asunción Ballester Martínez, Patricia Bassas-Freixas, Juan Luis Castaño-Fernández, Andrea Estébanez Corrales, Ricardo Suarez Fernández, Sergio Santos‐Alarcón, Ana Bauzá Alonso, Marina Torrent, Adrián Ballano Ruiz, Cristina Collantes Rodríguez, Agustı́n España, Eduardo Fonseca Capdevila, Inmaculada Gil Faure, C. Hernández-Fernández, Francisco Javier Melgosa Ramos, Jorge Spertino, Violeta Zaragozá Ninet, Lucia Armillas, Isabel Bielsa, C. Carrera, Mireia Esquius Rafat, Jon Fulgencio Barbarin, Javier Fernandez Vela, Miguel Lova Navarro, Clara Martín Callizo, Sara Martín-Sala, R.M. Ojeda, Maria Elisabet Parera Amer, Anna Sánchez Puigdollers, Ramón M. Pujol, Sebastián Podlipnik, José M. Mascaró, Laia Curto‐Barredo
Abstract
BACKGROUND: Bullous pemphigoid (BP) affects elderly individuals with multiple comorbidities, making conventional treatments unsuitable. OBJECTIVES: Evaluate the effectiveness and safety of dupilumab in the treatment of BP. METHODS: A multicentre ambispective cohort study was conducted across 34 hospitals. Patients with BP treated with dupilumab were included. Most of the patients (97.1%) received an initial 600-mg dose followed by 300 mg every 2 weeks. The primary outcome was the proportion of patients achieving complete remission (CR) within 4 weeks, defined as an Investigator's Global Assessment score of 0 or 1. CR at weeks 16, 24 and 52, adverse events (AEs), reductions in Peak Pruritus Numerical Rating Scale (PP-NRS) and systemic glucocorticoid use were also assessed. RESULTS: The study included 103 patients with a median age of 77.3 years; 58.3% were male. CR was achieved by 53.4% within 4 weeks and 95.7% by week 52. The PP-NRS score reduced by 70.0% by week 4 and was completely controlled by week 24. Thirteen patients presented with AEs, most of which were mild. Systemic glucocorticoid use reduced by 82.1% by week 52. Shorter disease duration and exclusive cutaneous involvement predicted better response at 16 weeks. No differences in response rates to dupilumab were observed between drug-associated BP and idiopathic cases. No significant difference in response rates was observed between patients treated with dupilumab in monotherapy and those receiving dupilumab with concomitant treatments. CONCLUSIONS: Dupilumab is effective, rapid and safe in managing BP, reducing the need for corticosteroids and other treatments. Early initiation and exclusive skin involvement predict better outcomes.